



10745 Westside Way, Suite 200  
Alpharetta, GA 30009  
Tel: +1 (844) 884 5367  
Email: [info@vtivision.com](mailto:info@vtivision.com)  
[www.vtvision.com](http://www.vtvision.com)

[www.vtvisioninvestors.com](http://www.vtvisioninvestors.com) (for investors)

## ASX Announcement

### Notice given under Section 708A(5)(e) of the Corporations Act

**Atlanta, Georgia, USA 21 August 2018:** Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company (**Visioneering** or **Company**) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) Contact Lenses, gives this notice under section 708(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) (as modified by ASIC Class Order 14/827 (**Class Order**)).

#### Background

Visioneering announced on 15 August 2018 that it had received commitments from sophisticated and professional investors to subscribe for 49,200,000 CHESS Depository Interests (**CDIs**) (representing the same number of shares of Class A common stock (**Shares**)) at A\$0.18 per CDI to raise approximately A\$8,856,000 (**Placement**).

The Company has today issued 49,200,000 CDIs (representing the same number of Shares) to complete the Placement (**Placement CDIs**). The Placement CDIs rank equally with the existing CDIs on issue.

#### Statements by Visioneering

Visioneering relies on section 708A(5) of the Corporations Act (as modified by the Class Order) and gives notice that it has issued the Placement CDIs without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, Visioneering:

- 1 has complied with sections 601CK and 674 of the Corporations Act; and
- 2 confirms that, there is no information:
  - (a) that has been excluded from a continuous disclosure notice required to be given to ASX in accordance with the ASX Listing Rules; and
  - (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of Visioneering; and
    - (ii) the rights and liabilities attaching to the securities of Visioneering,to the extent to which it would be reasonable to investors and their professional advisers to expect to find such information in a disclosure document.

- ENDS -

<b>Company</b>	<b>Investor relations</b>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: <a href="mailto:kwilliamson@buchanwe.com.au">kwilliamson@buchanwe.com.au</a>

**About VTI:**

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and received the CE Mark in early 2018, and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

**Foreign ownership restrictions:**

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.